Tesaglitazar
货号：
16791-1mg 基本售价：
406.0 元 规格：
1 mg
产品信息
概述| 货号 | 16791-1mg |
| 描述 | Peroxisome proliferator-activated receptors (PPARs) are activated by fatty acids and eicosanoids as well as antidyslipidemic agents. Among the receptor isotypes, PPARα demonstrates a particular role in fatty acid oxidation whereas PPARγ is known to be involved in adipocyte differentiation and lipid storage. Tesaglitazar, a dihydro cinnamate derivative, is a dual agonist of PPARα and γ that demonstrates IC50 values of 1 and 0.2 µM, respectively in ligand binding assays.1 At 3 µM/kg/day for three weeks, tesaglitazar has been used to reduce insulin resistance in obese Zucker rats.2 Furthermore, it has been investigated clinically for its potential to address disorders in glucose and lipid metabolism in patients with type 2 diabetes.3 |
| 别名 | AZ 242;GalidaTM; |
性能| 供应商 | Cayman |
| 应用文献 |
1.Cronet, P.,Petersen, J.F.W.,Folmer, R., et al. Structure of the PPARα and -γ ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure 9(8), 699-706 (2001).
2.Wallenius, K.,Kjellstedt, A.,Thalén, P., et al. The PPARα/γ agonist, tesaglitazar, improves insulin mediated switching of tissue glucose and free fatty acid utilization in vivo in the obese zucker rat. PPAR Research 2013, 1-14 (2013).
3.Wilding, J.P.H.,Gause-Nilsson, I.,Persson, A., et al. Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes. Diab.Vasc.Dis.Res. 4(3), 194-203 (2007).
|
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 408.5 |
| 分子式 | C20H24O7S |
| CAS号 | 251565-85-2 |
| 稳定性 | ≥ 2 years |
声明| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |
